Video
Author(s):
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
IMA203 Displays Efficacy in Heavily Pretreated Melanoma
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status
Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma
Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress